Wang Yichao, Xie Jiaogui, Liu Zhili, Fu Hongwei, Huo Qianyu, Gu Yajun, Liu Yunde
School of Medical Laboratory, Tianjin Medical University, Tianjin 300070, P.R. China.
Department of Hepatobiliary Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710032, P.R. China.
Exp Ther Med. 2017 May;13(5):2577-2583. doi: 10.3892/etm.2017.4235. Epub 2017 Mar 20.
Measurement of disease activity in patients with systemic lupus erythematosus (SLE) is important for monitoring disease progression and evaluating the therapeutic effects. The severity of organ damage correlates with clinical status and prognosis. Therefore, it is imperative to find an effective biomarker measuring disease activity and organ damage for SLE management. The present study investigated the possibility of serum calreticulin (CRT) in the assessment of disease activity and organ damage in SLE patients. Serum CRT levels from 80 patients with SLE, 55 patients with other autoimmune diseases and 60 healthy controls (HC) were measured by ELISA. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores. Organ damage was evaluated with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. CRT levels in SLE were significantly higher than that in other autoimmune diseases and HC. CRT was correlated with SLEDAI-2K score (r=0.3345, P=0.0024), and with anti-double-stranded DNA (anti-dsDNA) (r=0.4483, P<0.0001). A significant negative correlation of CRT levels with complement 3 (r=-0.3635, P=0.0009) and complement 4 (r=-0.3507, P=0.0014) was observed in patients with SLE. Furthermore, the patients with SLE and a positive anti-Ro52 result had higher levels of CRT compared with those with a negative anti-Ro52 result (P<0.001). Elevated levels of CRT were also reported among patients with SLE who also indicated the presence of cumulative organ damage. In addition, increased expression of CRT correlated with the presence of lupus nephritis. In conclusion, the results of the current report provided that CRT may be used as a potential biomarker for clinical diagnosis and of prognosis, providing additional information regarding disease activity and organ damage alongside other traditional indices.
测量系统性红斑狼疮（SLE）患者的疾病活动度对于监测疾病进展和评估治疗效果至关重要。器官损伤的严重程度与临床状况和预后相关。因此，寻找一种有效的生物标志物来测量SLE的疾病活动度和器官损伤对于SLE的管理势在必行。本研究探讨了血清钙网蛋白（CRT）在评估SLE患者疾病活动度和器官损伤中的可能性。采用酶联免疫吸附测定法（ELISA）检测了80例SLE患者、55例其他自身免疫性疾病患者和60例健康对照者（HC）的血清CRT水平。使用系统性红斑狼疮疾病活动指数2000（SLEDAI - 2K）评分评估疾病活动度。用系统性红斑狼疮国际协作临床/美国风湿病学会损伤指数评估器官损伤。SLE患者的CRT水平显著高于其他自身免疫性疾病患者和HC。CRT与SLEDAI - 2K评分相关（r = 0.3345，P = 0.0024），与抗双链DNA（抗dsDNA）相关（r = 0.4483，P < 0.0001）。在SLE患者中观察到CRT水平与补体3（r = - 0.3635, P = 0.0009）和补体4（r = - 0.3507, P = 0.0014）呈显著负相关。此外,抗Ro52结果为阳性的SLE患者的CRT水平高于抗Ro52结果为阴性者（P < 0.001）。在有累积器官损伤迹象的SLE患者中也报告了CRT水平升高。此外，CRT表达增加与狼疮性肾炎存在相关。总之，本报告结果表明，CRT可作为临床诊断和预后的潜在生物标志物,与其他传统指标一起提供有关疾病活动度和器官损伤的额外信息
